Ebola Treatments: FDA, NIH Developing New Clinical Trial Protocol
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA inks agreement with WHO to allow exchange of non-public information about medical products.
You may also be interested in...
Coronavirus Sponsors Should Get Responses To Regulatory Requests Within One Day, US FDA Says
As part of the new Coronavirus Treatment Acceleration Program, FDA staff also are being reassigned to handle investigational therapy requests faster.
Ebola Threat Prompts EU To Focus On Adaptive Licensing
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
PDUFA Collections Exceeded Target In FY 2021, While GDUFA Fell Short
The US FDA reports that the prescription drug user fee program met 27 of its 29 commitments by the end of FY 2021 and the biosimilar user fee program is on track to meet 16 of 27 of its performance enhancement goals.